Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Change in Accured Expenses (2016 - 2025)

Acro Biomedical has reported Change in Accured Expenses over the past 10 years, most recently at -$1315.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$1315.0 for Q4 2025, down 25.6% from a year ago — trailing twelve months through Dec 2025 was -$36878.0 (down 230587.5% YoY), and the annual figure for FY2025 was -$36878.0, down 230587.5%.
  • Change in Accured Expenses for Q4 2025 was -$1315.0 at Acro Biomedical, down from $23404.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ACBM hit a ceiling of $65500.0 in Q3 2023 and a floor of -$47685.0 in Q2 2025.
  • Median Change in Accured Expenses over the past 5 years was $442.0 (2024), compared with a mean of $4353.8.
  • Biggest five-year swings in Change in Accured Expenses: soared 1010.17% in 2023 and later crashed 10888.46% in 2025.
  • Acro Biomedical's Change in Accured Expenses stood at $4000.0 in 2021, then skyrocketed by 1291.78% to $55671.0 in 2022, then plummeted by 97.47% to $1408.0 in 2023, then crashed by 174.36% to -$1047.0 in 2024, then decreased by 25.6% to -$1315.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$1315.0 (Q4 2025), $23404.0 (Q3 2025), and -$47685.0 (Q2 2025) per Business Quant data.